KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma.
Pier Francesco FerrucciAnna Maria Di GiacomoMichele Del VecchioVictoria AtkinsonHenrik SchmidtJacob SchachterPaola QueiroloGeorgina V LongRosalie StephensInge Marie SvaneMichal LotemMahmoud Abu-AmnaEduard GasalRazi GhoriScott J DiedeElizabeth S CroydonAntoni RibasPaolo Antonio Asciertonull nullPublished in: Journal for immunotherapy of cancer (2021)
In BRAF V600E/K-mutant advanced melanoma, pembrolizumab plus dabrafenib and trametinib substantially improved PFS, DOR, and OS with a higher incidence of TRAEs. Interpretation of these results is limited by the post hoc nature of the analysis.